INTRODUCTION
In late nineteenth-century Britain serious attempts were made to promote science, to provide better educational facilities for scientists, and to increase the application of the sciences in industry and commerce. These included the Great Exhibition of 1851, with its emphatic display of scientific achievements; the internal reorganization of the Royal Society and its administration of a government grant to support research; the indefatigable efforts of T. H. Huxley and his associates to publicize science and its possibilities; and the increasing number of expressions of concern about the economic advantages gained by industrial competitors, particularly in Germany, which enthusiastically embraced and furthered scientific methods. 1 However, there were also appreciable reservations about these new approaches; and in the medical world in particular, considerable ambivalence was expressed towards science and its practitioners. Therewas, forexample, ready acceptance that claims to scientific expertise could confer additional status on medical practitioners and enhance the reputation ofthe medical profession. Nevertheless, there was also distrust, and even distaste, for an endeavour that was seen to belong more to the artisan class than to the gentlemanly profession that medicine had become.2 The pharmaceutical sciences, such as they were at this time, were especially subject to these contrary pressures. Within the developing pharmaceutical industry itself, a small but growing number of agitators compared the lack of scientific support in Britain with the strong encouragement lent to research in some American and European countries, by governments and the manufacturers themselves. At the same time, however, many medical men felt threatened by new scientific developments that they saw as encroaching upon their traditional skills; whilst others were openly disdainful of such tradesmen as chemists and druggists claiming scientific ambitions that properly belonged to the medical profession.
auspices of Burroughs Wellcome and Co., which encouraged the raising of antitoxins against other diseases.20 By 1896, the rapid development of, and associated demand for, sero-therapy led to a move from Portland Place to larger facilities at 40 Charlotte Street. By this time, it was becoming obvious to Wellcome that animal experimentation was required not only to test, quantify and standardize diphtheria antitoxin, but also to develop and expand the chemo-therapeutic work of the company by promoting vigorous physiological testing of animal-derived and chemically-manufactured pharmaceutical preparations. At the same time, the work of the laboratories was brought to the attention ofthe Home Office and in May 1896 it advised Wellcome that application should be made to register the premises, in accordance with the 1876
Cruelty to Animals Act, for the purposes of testing antitoxins.21 THE CRUELTY TO ANIMALS ACT, 187622 The proposal, and subsequent passing, of the Cruelty to Animals Act (39 & 40 Vict., c. 77) stimulated great debate both in and outside Parliament. 23 The Act, which applied to experiments calculated to give pain, required every researcher to hold a personal licence, granted on the recommendation of two eminent medical or scientific authorities. Such licences were available for use only at specified premises registered with the Home Office; and certain classes of experiments required the additional sanction of Certificates (described below), also granted on the personal recommendation of eminent persons.24 The Act did state that "private places, in addition to public laboratories, could be occasionally made legally available for purposes of research experiment", but required a licensee to "perform his experiments at a place registered by the Home Secretary and subject to inspection at any time". The 180:WPRL show the laboratories at 40 Charlotte Street in autumn 1896; prior to this they were at 10 Devonshire Street, Bokenham's address in the Medical Directory from 1895 until 1898. 20 BW&Co to Bokenham, 8 April 1895, mentions antitoxins for consumption; BW&Co to Bokenham, 29 April 1895, refers to serum therapy for erysipelas, puerperal fever, etc. "we would like you to proceed with your investigation of this with all urgency. We think it very important that we should be in the forefront with this". Wellcome to Bokenham, 15 May 1895, discussed increasing large animal immunity. All in WF:HSW Letter Books 1881-1895, S/G/148/2 pp. 673, 682, 689. Chem. & Drug., 1896, 48: 825 reported a French anti-choleraic serum; the copy in the Wellcome Institute (originally from BW&Co) has the marginal mark in Wellcome's writing "notify Bokenham". Anti-streptococcus serum was "prepared by myself, and supplied to the profession through the firm of Burroughs, Wellcome and Co.": T. J. Bokenham, 'Additional notes on the preparation of anti-streptococcus serum', Br. med. J., 1896, ii: 3-4. "registered" and people were "licensed", has been employed throughout this paper; contemporary usage often confused the two and direct quotes retain the original words. Confusion also arose over definitions of "experiment", "cruelty", and "pain": see R. S. Vine, 'The history of the Research Defence Society', Conquest, 1987, 176: 1-16 . Likewise, the Cruelty to Animals Act was often incorrectly referred to as the "Anti-Vivisection" or "Vivisection" Act. 23 See French, op. cit., note 3 above. 24 These were medical professors, and the Presidents ofthe Royal Societies of London and Edinburgh and the Royal Colleges.
5
Inspectors were themselves medical men. G. D. Thane, for example, who was closely involved with Wellcome's application, was Professor of Anatomy at University College London.25 Although in the early years of the Act such "private places" as the "cellar at 13 Claremont, Bradford" (1886) were registered, by the 1890s most experiments were performed in university or hospital laboratories.26 There were two questions relevant to the antitoxin work of the Wellcome laboratories: did the raising of diphtheria antitoxin itself require a licence (and hence have to be performed on registered premises)?; and did the testing and quantification of the antitoxins require a licence? Such problems had concerned the Home Office for many years. As early as December 1879, similar questions were referred to the Law Officers of the Crown for Opinion, and they were raised again in 1894, 1895, and 1896. The variety of views expressed indicate considerable confusion.27
The 1879 Opinion was that the initial inoculation to raise antitoxins did not appear to be an experiment under the Act, but that if a Certificate was required for the work, it would have to be Certificate A, i.e. for experimentation without anaesthetics. The Law Officers cautioned that, in the public mind, Certificate A was associated with painful, rather than relatively painfree, experiments; and, (just three years after the passing of the Act), that the language of the Statute was ill-defined. The 1894 Opinion was that raising antitoxins was not an experiment as it was not for the ascertaining ofa scientific truth, but that some pain might occur if, for example, excessive quantities of blood were drawn. The same Law Officers offered a substantially different Opinion the following year when the question was again referred to them: "inoculations for the purpose of testing the efficacy of a substance known to be a cure for disease and produced for the purpose of being used in particular cases, is [sic] not an experiment within the meaning of the Act." They therefore declared that inoculations made for the diagnosis or cure of disease were outside the 1876 Act. However, they maintained that similar work performed for scientific curiosity alone was an experiment, and suggested that the problem could be resolved by obtaining a binding legal decision in court. A few months later, different Law Officers offered a different Opinion: the raising of 25 French, op. cit., note 3 above, pp. 143-4. The appointment of medical men as Inspectors was not uncontroversial, e.g., "one wonders whether an Inspector in such a position might possibly again, even unwittingly have overlooked some small infringement of the act in the interests of his own profession": J. Pellow, The Home Office 1848-1914, from clerks to bureaucrats, London, Heinemann Educational Books, 1982, p. 198. 26That antitoxins in horses or asses was not an experiment because it was done to produce a particular, specified substance and not for scientific enlightenment; but testing procedures on small rodents were experiments for medical purposes and therefore within the Act, as the Act did not specify that it applied only to work for the advancement ofknowledge. A further question as to whether such work was calculated to give pain evoked the response that the Act was hardly designed to cover such minor discomfort as that endured by a child with measles, but that a legal decision, obtained by a prosecution, might clarify the situation.
Thus, by the time of Wellcome's application in mid-1896, Home Office directives were that the use of an animal for a procedure of which the outcome was known and which was not calculated to cause pain, i.e. the raising of diphtheria antitoxin, was not an experiment and therefore did not come under the 1876 Act. However, the experimental use of animals for raising new antitoxins and for all testing and standardization procedures did come under the Act. For such work the premises had to be registered, and the researchers needed valid Home Office licences and, when necessary, the appropriate Certificates allowing particular experiments to be performed on specified animals.28 Consequently, Bokenham The Inspector recognized that "The discovery of antitoxins has led to their preparation on a large scale; but, as these remedies cannot be safely and effectually used on human beings without being previously tested upon rodents, the preparation of antitoxins has necessitated a large number of inoculations."38 This indicates quite clearly Home Office sensitivity about the increase in animal experiments and its concern to relate the work to therapeutic advances. It might be significant, therefore, that during 1896, when Bokenham applied on behalf of the WPRL, there was no increase in the total number of registered places. He further informed the Home Office that there was no longer adequate space available for him at either the Conjoint or St Bartholomew's laboratories, and that if they had not intended to register the Wellcome laboratories, then the Home Office letter of 4 May (suggesting that Wellcome apply for registration) was "quite unjustifiable and a deliberate attempt to mislead us and to give us unnecessary trouble".48 Not suprisingly, Home Office officials considered this to be "an illmannered letter" although they noted that "it contains the important argument that the applicant finds it impossible to obtain space for his experiments".49 Despite Bokenham's assurances that "My authority for this statement is unquestionable"; the Home Office sought its own verification and eventually concluded that Bokenham had made no application for further space and was not even using the facilities already available to him.50
In the meantime, the Wellcome laboratories moved to their newly equipped premises in Charlotte Street, with stabling facilities for eight horses in Lisson Grove, and diphtheria antitoxin production continued. Whether Bokenham intended to proceed with his arguments against the Home Office is not known: several problems arose with the serum production that may have distracted his, and the Company's, attention from the problems of registration. below the claimed "strength" (in numbers of antitoxin units per vial); the specific charge against Burroughs Wellcome and Co. was that instead of the advertised 600 units per vial, the tested strength was from 45 to 300 units in the liquid serum (6 samples) and from 40 to 300 units in the dried serum (5 samples).54 According to the Chemist and Druggist, this report provided one more example of the "'made-in-Germany' problem which haunts British technologists", and it was noted that the German Government offered support and facilities at several levels for the production of antitoxin far beyond that available to British manufacturers. Strangely, but perhaps significantly, the problems of British firms working within the 1876 Act were not mentioned, despite the strong assertion that "Guinea-pigs are the test-tubes in an analysis of this kind". A simultaneous report in the Pharmaceutical Journal, about animal-derived therapeutics, provided a rare acknowledgement that
The preliminary investigations must of necessity be carried out by the physiologist, but the chemical work now falls to the lot of the manufacturing chemist, and as patient physiological investigations are necessary, they are principally prepared in Germany, under medical supervision, and without the vexatious interference of the Vivisection Act.
However, the same journal's later call for British manufacturers to "set their house in order" over drug standardization ignored the particular restrictions and problems imposed by the 1876 Act.55
The Lancet survey provoked questions in the House of Commons about the low standards of British manufacturers compared with their Continental, particularly German, counterparts, but again there was no mention of the legal constraints operating in Britain.56 The report caused a considerable stir within the Wellcome organization and letters to the Lancet from both the Company and Bokenham questioned the discrepancies highlighted by the Special Commissioners and offered every facility for further joint testing under an independent authority.57 Although press commentators applauded this response, it was rejected by the Lancet as incompatible with who took the Commissioners' report and the Lancet's refusal of joint testing personally, injudiciously claimed, " . . . I know that the results obtained by your Commissioners are incorrect", and questioned the experience and expertise of the Commissioners in comparison to his own.60 Not suprisingly, the Lancet responded strongly to these "preposterous" allegations and maintained that "Messrs. Burroughs, Wellcome & Co. owe it to their well-merited reputation for drugs that this question should be placed on some more satisfactory footing."6' At this point, Henry Wellcome himself became involved in the defence of the good name and the commercial standing of the company, of which he was now the sole proprietor. He wrote to Bokenham for precise details of the samples tested by the Lancet, sought the advice of Fletcher Moulton and referred the entire issue to Chune Fletcher.62 He instructed J. C. Smith from the Company to ascertain what steps Bokenham had taken and to explore the possibility of an independent referee re-testing the disputed serum. Smith discovered that samples corresponding with those tested had not been retained, although it was possible to obtain duplicates from the Lancet, and reported that he and Bokenham could come to no agreement about a suitable referee. it no longer. At the end of September, he wrote to Bokenham, urging him to take the "honourable" course of resigning, and offered three months' salary plus the month's salary owing to him and the three month's salary in lieu of notice as agreed in his contract. Furthermore, Wellcome promised not to mention the manner of Bokenham's departure, in consideration of his professional position.84 Bokenham's reply, if any, is not on record.
Laboratory equipment and materials were transferred to Cobbett and Dowson, who "will take over control of our Physiological Laboratories and Stables" and formal arrangements were made with Dowson, who was appointed Director of the Laboratories at the beginning of October85 with the clear proviso, stated in his contract, that any publications must have Wellcome's approval, and that he was "to advise us on all physiological questions arising in our business when requested to do so".86
After these changes the laboratories continued to produce antitoxins and there were no further major problems about contamination or strength.87 The arrangements with Kanthack and Cobbett lapsed whilst the demand for serum necessitated expansion. The facilities in Charlotte Street were seen to be inadequate and in 1898 the Company began looking for new premises for the WPRL.
THE MOVE TO HERNE HILL AND THE DEVELOPMENT OF RESEARCH
In August 1898, Brockwell Hall in Heme Hill, South London, was identified as a suitable site, and in November Henry Wellcome acquired a long-term lease on the property and undertook its extensive conversion, "carried out at very great expense, and no pains, labour, or money have been spared in rendering the equipment and appointments most complete."88 By May 1899, Dowson and his small staff had moved from Charlotte Street89 and it was at this point that the establishment was publicly recognized as the Wellcome Physiological Research Laboratories. Descriptions of the experimental laboratories, incubation chambers, packing rooms, and stabling facilities soon appeared in professional journals and in the WPRL's own publications and advertisments.90 There were facilities for bacteriological, chemical, matter was never entirely dropped after Bokenham's earlier application,98 and by 1899 the expense and inconvenience of performing experimental work at other registered premises, especially from the WPRL's location in South London, were becoming obvious.99
Publicity for the new laboratories, such as that quoted above from the Chemist and Druggist, attracted attention from anti-vivisectionists who, in turn, alerted the Home Office that serum-testing was being carried out at the WPRL.100 At the end of 1899, Dowson visited the Home Office Inspector, Professor Thane, and freely admitted that such procedures were performed at the WPRL, but he believed that they were not covered by the Act as they were not calculated to give pain. Once more, Home Office staffconsulted the previous Legal Opinions and although a Home Office official noted that it "seems morally certain that nothing amounting to illegal infliction of pain takes place in this establishment" Thane was asked to visit "ifthe Firm will let him do so". 101
Thane acknowledged in his request "that the premises not being registered, I have no right of inspection . guinea-pigs with the serum from these animals in order to ascertain its antitoxic strength. The latter they regard as an experiment, the former they do not.'04
Thane's report to the Home Office was as enthusiastic as his predecessor's had been in 1896: "These are excellent laboratories, Chemical and Bacteriological, well arranged and equipped for work of the highest kind". He also reported positively on the stabling facilities for the thirty horses under diphtheria treatment, and the housing for the guinea-pigs used in the testing operations, noting that the only other animals at the WPRL were two goats kept as pets.105 His report concluded that many press accounts of the laboratories referred to projected work, for which official sanction would be sought, and that he did not in any way wish to suggest that the laboratories should be prosecuted. However, he admitted that the testing of antitoxins under the 1876 Act was still an open question: he believed that as a matter of fact, although not of legal opinion, diphtheria antitoxins did not cause pain and did not therefore come under the Act. However, the Law Officers' Opinion of 1896 was used in interpreting the law, and therefore production of antitoxins could continue quite legally at Brockwell Hall, but testing and standardization were still to be performed on other, registered, premises.
THE APPLICATION FOR REGISTRATION, 1900
In February 1900, Wellcome again petitioned the Secretary of State for the Home Department, Sir Matthew White Ridley, for the registration of the WPRL.106 He presented clear scientific and economic reasons for his application, detailing the outstanding facilities of the laboratories, and stressing the importance of drug standardization and the urgent need for experimental physiological techniques to achieve the level of reliability of some imported pharmaceutical products. In particular, the development and evaluation of new therapies, especially those associated with animal products, demanded physiological experimentation and quantification.107 The introduction of large numbers of useless therapeutic novelties into Britain could be avoided if proper physiological analysis and testing was introduced.
It is not going too far to assert that the administration of all powerful remedies to human beings should first of all have a sound basis in laboratory experiment. This remark applies equally to that class of remedies in which the relation between the chemical constitution and physiological action might permit modifications to be introduced with the result that their usefulness would be greatly enhanced, as to new therapeutic agents which are from time to time being discovered in the field of nature and in the chemical laboratory. ' He further maintained "that medical science is entering upon an advanced phase in which clearly recognised disease conditions are to be met by the administration in various ways of remedies with definite determined properties in exact doses."'109
Coupled with these scientific justifications was the businessman's argument that the manufacture of fine medical-chemical products in Britain had been severely limited by the lack of precise physiological testing. "This", Wellcome concluded, "with all it involves in loss of trade, loss ofemployment to the citizens of this country in a field where they could excel, and loss of prestige is all the more serious because it is unnecessary." Similar arguments had been developed in the pharmaceutical press. The Chemist and Druggist, in noting German provisions for industry, lamented that
With such enterprise and with such scientific resources at command it is not surprising that in the production of fine chemicals British manufacturers have been to a large extent beaten out of the field. English discoveries of great practical value have, indeed, been carried off and utilised by Germans right under our noses.
Their recommendation that Britain needed "firms willing to risk ten, twenty or thirty thousand pounds annually on what might be unprofitable research" ignored the existing legal constraints. II Wellcome's financial ability and willingness to promote such research was also subject to the additional restrictions of the 1876 Act, and his application for registration painstakingly distinguished his commercial operations from the research ventures that he supported, although this seems to contradict some of his previous assertions. 11I
These laboratories are entirely separate and distinct from the works and business departments of Burroughs, Wellcome and Company. They are under independent direction and are conducted as strictly professional institutions. They are not carried on as a source of profit but are maintained at a heavy cost by funds derived from other sources, and like the Wellcome Chemical Research Laboratories (6 King Street, Snow Hill, London E.C.) have been designed and equipped for research work. At the present time, however, this research work is fettered and hindered by the inability to staff, employed by the Company. 114 And after all, the raising of diphtheria antitoxin for sale by the Company had been the raison d'e2tre for the WPRL. Wellcome consistently stressed that the serum was sold below cost price, and seems to have equated the absence of profit with divorce from commerce.
Widespread prejudice against his "trade" associations became manifest when he and his staff attempted to rally both direct and indirect support for the registration application."15 Initially a copy of Wellcome's petition was sent to several prominent medical men, asking for their support "As the subject is one of practical importance to the medical profession and to the public"."16 The intention was to approach thirty-five individuals and four organizations. 117 and Teachers in our great Schools of Medicine and Universities" were almost insuperable and that it was therefore unreasonable to request additional facilities for "firms engaged in business" although he recognized that Burroughs Wellcome and Co. did excellent work. He also raised the question that would recur throughout the period of Wellcome's application-if the Home Secretary did register the WPRL, the privilege could not then be withheld from other, "inferior" firms.'25 Dowson received this opinion with considerable dismay and immediately refuted some of the objections: "my own feeling is, and this was the point which weighed with those who have already signed, that the principle of the thing is right, and that results would be good both for the medical profesion and for the public." He argued that those who would benefit most from the registration of the WPRL and other "commercial" laboratories would be the sufferers from disease, "not to mention the advantages which must accrue to the science of a very difficult subject"'.'26
Within the Wellcom.e organization, it was thought that the application would go before the Home Secretary himself who would then pass it to the Law Officers of the Crown or to the Association for the Advancement of Medicine by Research (AAMR). Dowson knew that the latter had been approached when the Clinical Society requested registration, but there is no record that they were involved with the Wellcome application, and in view of its generally facilitatory role and the fact that many of its members had signed Wellcome's petition, it seems unlikely that its opinion was canvassed. '27 In May 1900, Dowson's contract was extended for three years, and he was provided with a letter ofindemnity, approved by the Company's legal advisers, in which " [ Church also raised the possibility of either the Conjoint Laboratories or the Jenner Institute becoming Official Testing Stations, although he stressed that pecuniary assistance would be necessary. 133 The Laboratories Committee reported in July 1900. While supporting the need for some animal experimentation for drug standardization, it regarded "the authorisation of the necessary experiments in the premises of manufacturing chemists as highly undesirable". 134 Perhaps not too surprisingly, the Committee praised the work of the Royal Colleges, which in the public interest and without financial advantage had for many years produced and tested serum at stables made available by the Metropolitan Asylums Board and funded by the Goldsmiths Company.'35 It explained the existing provision of a Testing Service for other manufacturers' serum, and suggested that such "independent" validation was more authoritative than any performed by the manufacturers themselves. 136 This arrangement was already working well with Parke Davis and Company.'37
These reports came to Wellcome's attention and he realized that the Home Office would require additional reasons before granting registration.138 A draft document prepared by the Wellcome organization emphasizes that the work undertaken at the WPRL should not be misunderstood. "Research work is not a thing which can be made to pay and these departments are carried on as strictly ethical institutions quite distinct from manufacturing departments."'39 Perhaps to highlight this point, the Company sought press coverage of the work of the WCRL, which had actually moved to new premises some months previously. The resulting reports, which fortuitously praised the scientific quality of the work and the professional standards of the staff, and lauded "Mr. Wellcome's public spirit", also emphasized the independence of these laboratories from the Company: "the clovenhoof of commercialism has not appeared in Mr. Wellcome's scheme".'140 A concerted effort was now made to achieve registration: staff of both the WPRL and the WCRL were asked to submit ideas for a new petition and Fletcher Moulton's 
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The Wellcome Physiological Laboratories legal advice was sought once again.'4' Dowson was dispatched for an informal talk with Professor Thane at University College, with instructions to withdraw the petition rather than risk an outright rejection, if that seemed the likely outcome. 142 This visit was to prove of critical importance as Dowson realized "that a crisis was on us" and after appealing to Thane "as one scientific man to another", he learnt that a formal letter of refusal was about to be sent to Wellcome from the Home Office. Dowson sped to the Whitehall office of Sir Kenelm Digby, and after a lengthy discussion during which he extracted the admission that the Wellcome petition "was one of the more important and one of the most difficult to deal with that they had before them for years", he finally persuaded Digby not to send the letter and to allow Wellcome more time to supplement his petition. '43 An even more significant outcome of this visit was Dowson's declaration of readiness to testify that the diphtheria antitoxin testing procedures were painless, if legal proceedings were taken against him. Digby recorded that "Dr Dowson has thrown down a distinct challenge to the Home Office to test this, and I cannot blame him for doing so. It seems to me a perfectly open and straightforward course to take."'44 However, as Digby wrote, it would pose several problems for the Home Office: proceedings could indeed be initiated, but it seemed unlikely that the prosecution would be successful, particularly as Thane was not prepared to argue that such procedures were painful. A failed prosecution would open the Home Office to complaints from anti-vivisection groups that they had not been consulted, and such conflict should be avoided if possible. The Secretary of State could once more refer to the Law Officers and ask for specific advice about a prosecution. Alternatively, if the matter was now too important for the Home Office alone, a strong inter-departmental committee should be established to consider the broader issues of scientific advances and their commercial applications, and non-scientific men, including opponents of animal experimentation, should be invited to participate. ' It is worth considering whether prejudice existed against Wellcome, not just as a "tradesman", but as an American. Although Wellcome was a prominent member of the American Society of London, and there had been an earlier suggestion that Burroughs Wellcome and Co. had been subject to nationalist prejudices, Wellcome himself stoutly maintained, "I have never had reason to feel myself either a stranger or a foreigner in this country". No evidence has been found amongst Home Office, or any other, records that Wellcome was discriminated against as a foreigner (although see below on the comments expressed in 1905), and contemporary accounts of American business activities were usually favourable. Lord Rosebery, for example, used a particularly apt analogy: "In these days we need to be inoculated with some of the nervous energy of the Americans".158 What was of concern in Britain at this time were the activities of the various anti-vivisectionist movements and Wellcome had been especially annoyed at the way his Company's policy of cheap serum had been cynically disparaged in the Abolitionist.159 This attack was particularly inopportune as it occurred whilst the registration petition was under Home Office consideration. However, Dowson's Whitehall contacts advised him that they were actually more afraid of repeating the "Coal-Tar Industry mistake",'60 a reference to the decline of that industry despite its calls for Government support. Wellcome's staff considered several ways in which their case for registration of the laboratories could be advanced. One plan was to issue explanatory booklets to all medical practitioners in Britain: eventually, more discreet advertising methods were employed.'6'
The Home Office had, of course, taken considerable notice of the opinions expressed by the two Royal Colleges. Dowson's private informants, as well as Fletcher Moulton, suggested that approaches should be made to all members of the Laboratories Committee, "in the hope of converting them from their conservative opinions, as probably their conversion means to us success or failure in this petition."'162 Thus Dowson began to visit and correspond with several prominent doctors and members of the Laboratories Committee; and his confidential notes to the Company'63 and subsequent report to WellcomeM 64indicate not only the extent of his canvassing but also the range of opposition that the WPRL faced from the medical authorities.
The Chairman of the Laboratories Committee, Dr P. H. Pye-Smith, was initially reluctant even to discuss the problem, claiming that "It is an official matter entirely". He relented eventually but argued that the precedent of the WPRL's registration would result in the granting of similar applications with no guarantee as to the quality of staff or facilities. The only retort that seemed to influence him was Dowson's reminder that licence and certificate applications had to be supported by responsible members of the profession. At the end of the interview he promised that "he would do what he could".165
The other member of the Laboratories Committee interviewed by Dowson, Dr Sidney Martin, was in "most decided and fixed opposition to Mr. W's desire", and although he expressed satisfaction with the work of the WPRL, he too believed that the Home Office might proceed to register inferior laboratories. The argument that Dowson had used so convincingly with Pye-Smith failed to satisfy Martin, who cited Bokenham as a conspicuous example of the failure to maintain standards.'66 Martin also doubted the independence of laboratories associated, however tenuously, with a commercial company, and he challenged Dowson to say whether, if a new method of precipitating and drying antitoxins was discovered in the WPRL laboratories, it would be published immediately. When Dowson replied "no", Martin re-emphasized his opposition to the registration of any but a purely scientific institution. He thought that it would be some time before such laboratories as the WPRL would be registered, although he also believed that the Home Office would not interfere with their present production of antitoxin.167
The Director of the Conjoint Laboratories, T. G. Brodie, while friendly towards the WPRL, was concerned that "We medical men must take care that experimental science, especially biological science, is not made subservient to commercial 162J. C 166 Martin does not seem to have realized that it was because Wellcome wished to be seen to be within the law that he was applying for registration.
interests", and was anxious to know how testing experiments were done at the unregistered premises of the WPRL. Dowson replied that such experiments did not give pain and were therefore outside the 1876 Act. Although Brodie agreed, he warned that many other physiologists did not, and that Martin, in particular, believed strongly that such work was painful and should come under the 1876 Act. Brodie already knew that the Home Office had written to several leading bacteriologists about this, and Dowson warned the Company that a directive might therefore be expected any day from the Home Office, stopping such work at the WPRL.168 Wellcome's handwritten comment at the side of this report is emphatic: "I shall seriously consider the question of establishing physiological testing laboratories abroad if we finally fail to get justice at home."'169 Thane investigated the first of these himself, visiting several laboratories to observe their experimental procedures. The majority, but not unanimous, view was that diptheria antitoxin testing did not cause pain.176
The second question was referred to both Royal Colleges, the Pharmaceutical Society, and the Jenner Institute. The problems of financing a central Testing Station seemed immense, as none of the bodies which supported such a venture was prepared to be responsible for its cost. The Government was unwilling to establish official laboratories itself, and Digby felt certain that if another body did not provide such facilities reasonably quickly, then the registration of the WPRL must be recommended. 177
The third point was clearly related to the first question and to Dowson's position, as a licence-holder, under the law. This was the crux of the request for the legal opinion which the Home Secretary addressed to the Law Officers of the Crown. The first draft of this document stressed, somewhat inelegantly, that the important question arises whether it is not doubtful whether such experiments are performed for "the purpose of advancing knowledge by new discoveries" as, if not, there appears to be no power to license them, and therefore, however useful, they 175 cannot be performed at all either with or without licence. If this were so, it is difficult to see how the important processes of standardising drugs and antitoxins can be carried on in any circumstances in which they would be calculated to give pain.'78
The memorandum pointed out that, if the Law Officers decided that testing experiments were breaches of the Act, a difficult administrative situation would arise. Such work will certainly be carried out by the Firm in France or Germany if not done here,-they are no more painful than numbers that are now being done every day for the "advancement of knowledge" and other admittedly scientific purposes, and if they are rendered impossible an important and lucrative branch of trade will have been driven from our country, the results of which are most useful in saving life and alleviating suffering.
The Law Officers considered that testing procedures were to be regarded as experiments and that the Secretary of State could not make his annual renewal of Dowson's licence if he knew that the law was being broken, although Dowson should not be prosecuted for past misdemeanours. An internal memorandum maintained that the Secretary ofState could not restrict experimentation at pleasure or out ofsentiment but could only refuse if the objects of the research were considered to be useless and/or if unfit persons were proposed to perform them: "If this is so, it settles this case, when once we are satisfied of the nature of the arrangements made." The Royal College of Surgeons might perform such operations better, but they could hardly perform them more painlessly. If the Secretary of State was convinced that the experiments were useful and necessary and were to be performed by qualified persons, then he should register Wellcome's premises. Professor Thane remarked: "If the request were acceded to, the question of the illegality of the proceedings would fall through in this particular case. Therefore, I These lengthy quotations indicate the force with which Wellcome now presented his request to the Home Office. Some of the assertions made in his first petition, especially on the basic need for laboratory testing, were included again in the new submission "I hold it to be wrong that a drug should receive an extensive trial lasting perhaps for years on the human subject without previous experiments on animals ... the administration ofall powerful or dangerous remedies should first have a sound basis in laboratory experiment."
In the middle of March there was an encouraging response from the Home Office in the form of a request for further details of experiments to be performed under licence and certificates, of who would be employed, and of the arrangements envisaged for planning and reporting experimental work.185 This was passed to Dowson, Smith, Chune Fletcher, and Fletcher Moulton, and "It was decided to immediately engage,if possible, another physiologist, upon the condition that the engagement should not be ratified unless we secured the license from the Home Office". This person was to provide the precise details required by the Home Office. Dowson was dispatched to interview Sir Michael Foster about a suitable candidate. 186 The initial draft reply to the Home Office was more succinct than those previously submitted. It listed the nature and number of experiments desired during the first year (e.g. antitoxin work on typhoid, tetanus and snake-bite; standardization work on digitalis, ergot, and lobelia, and purely experimental work on supra-renal gland extracts) and described the staffing arrangements and organization of the different departments of the WPRL.187
Throughout are spaces "to be filled in by the new physiologist" and by the date of the next draft, 21 May, "the new physiologist" was named as John Mellanby The file was once again passed to Professor Thane, who wrote a lengthy minute, weighing up the argumants for and against the registration of the WPRL. He made it clear that he considered it unreasonable to prevent a manufacturer from testing in guinea-pigs the serum he was allowed to raise in horses; and he emphasized the practical importance of such work, the eminent support that Wellcome had obtained, and the considerable development that was to be expected in such standardization work. These arguments were followed closely by Digby, who came "somewhat reluctantly to the conclusion that the application to register Messrs. Burroughs & Wellcome's laboratories must be granted. I say 'reluctantly' because I think that besides the outcry which will no doubt be raised by the Anti-vivisectionists, the Home Office will be taking a new departure, which will lead to some difficulties, but which in my view is inevitable."192 Thane was asked to visit the laboratories once more.
Dowson was recalled from his annual holiday to Brockwell Hall and J. C. Smith visited the laboratories to ensure a special "clean-up", prior to the meeting. Thane It is understood that you are to treat as strictly confidential, and respect as my property, all my manufacturing processes, formulae, apparatus etc. and all improvements therein, and also any inventions or new discoveries which may be made by you or anyone else in my employment; on the understanding that I shall not extract from you with respect to any discovery a confidence which is contrary to the ethics of your profession.
It is also understood that before publishing any communications upon physiological matters or upon any work connected with the Laboratories you are first to submit same to and obtain the approval of the Director.
The two clauses just written refer to work done at any time either in or out of the Laboratories. 200 The problem of offering such documents to scientific staffhad been raised by Chune Fletcher, who complained that the wording was totally unsuitable. He maintained that the annual holiday allowance of three weeks was insufficient for a good professional man, and that this was exactly the kind of restriction that would prevent such a person joining, or remaining in, the laboratories.201 He became even blunter about the necessity of Company policy not upsetting work at the WPRL so that they can make a thoroughly good start now that they are registered, every consistent concession should be made. The trouble and anxiety which we have had to secure men for these laboratories, has been exceedingly great, and one must not forget that the proportion of men sufficiently broad-minded to be associated with your laboratories is very small. With Dr. Dowson, Dr. Shaw and Mr. Mellanby we think there is a great opportunity for creditable work to be done at the laboratories, but they must have every encouragement and stimulant possible.202
In addition to serum production and diagnostic work, registration under the 1876 Act permitted Wellcome to employ physiologists and pharmacologists to prosecute "pure" research, and his most famous recruit was undoubtedly Henry Dale,203 who joined the WPRL in 1904. However, prejudices and misconceptions still prevailed and he was warned "I should be selling my scientific birthright ... for a mess ofcommercial pottage", although "I never had serious or lasting reason to regret the change which I had made".204 Indeed, Wellcome's request to E. H. Starling for a reference for Dale again emphasized the laboratories' independence from the commercial organization, and that he was looking for was performed at the WPRL after the granting of Home Office Registration. 208 One indication of the calibre of scientists recruited to the WPRL at Brockwell Hall is the number of them that were subsequently elected to Fellowship of the Royal Society. 209 It is pertinent to consider two further questions: did the Home Office's registration of the WPRL open the flood-gates to numerous "commercial" applications? and did the registration of the WPRL itself greatly increase the total number of experiments performed under the 1876 Act?
PHARMACEUTICAL COMPANIES AND HOME OFFICE REGISTRATION Difficulties with the Home Office were not entirely resolved with the granting of registration: in January 1902, Shaw applied for a licence and certificates to carry out cancer research.210 Not only was he identified in Home Office records as "a new Burroughs & Wellcome man" but continuing doubts were expressed about the work of the WPRL: "This raises the question whether the Burroughs & Wellcome Laboratories are to be used for general original research and diagnosis, or merely for the processes involving experiments under the Act, which are necessary for Messrs. B.&W.'s business".211
Inevitably, Professor Thane was asked for his opinion, and he produced a five-page report on the practicability of limiting work at the WPRL. This emphasized the word "research" in the title of the laboratories and Wellcome's intention, implicit in his application, of prosecuting research not directly associated with serum production or drug standardization. Thane stressed his belief that an application merely for such procedures would have been refused, and maintained that There is no doubt that Mr. W. desires to get research work done in, and scientific papers published from, his Physiological Research Laboratories, just as is the case with his Chemical Research Laboratories.
In the eyes of many persons it will be a merit that scientific work is done in the laboratory in addition to trade work. the importance of precedent,216 the very argument that caused so much concern at the time of Wellcome 
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total of 14,906, and thus contributed substantially to the increased returns for 1902. When the returns under A certificates are analysed separately, it can be seen from table 2 that the increase in such returns between 1901 and 1902 is 3,216, and of these 2,261 were experiments reported from the WPRL. In 1908, eleven licences were available at the WPRL, and they performed at least 5,266 experiments out of a total of 88,634.224 Thus in those six years the Wellcome returns had doubled, although the total returns had increased by almost a factor of six. The registration of the WPRL and similar "commercial" laboratories did not, therefore, increase the animal experimentation figures as significantly as had been feared during Wellcome's application for registration. 
